301047.SZ
301047.SZ
CNE100004Q23
SINO BIOLOGICAL
Loading chart...

Company Profile

Sino Biological,Inc. engages in the provision of recombinant protein and antibody reagents for life science researchers in China and internationally. The company offers recombinant proteins, antibodies, cDNA clones, kits, serum-free media, protein modification, qPCR primers, cell lysates, and purification reagents. It also provides comprehensive solutions, including autoimmune disease research, kinase drug discovery, cytokine and growth factor, SARS-CoV-2 variants research, comprehensive CAR-T therapy, 3D organoids research, ADC development, influenza vaccine development, and multispecific antibody development solutions, as well as solutions for MSCs therapy and in vitro efficacy evaluation. It serves academic research institutions, biotech companies, and pharmaceutical companies. Sino Biological,Inc. was founded in 2016 and is headquartered in Beijing, China.

Related stocks

301080.SZ
301080.SZ • China
ACROBIOSYSTEMS
122.2 CNY
3.06B USD 1Y +98.2%
9688.HK
9688.HK • China
ZAI LAB
19.25 HKD
2.75B USD 1Y -26.5%
688520.SS
688520.SS • China
SINOCELLTECH GROUP LTD
36.22 CNY
2.55B USD 1Y -35.8%
ZLAB
ZLAB • China
Zai Lab Limited
24.99 USD
2.81B USD 1Y -26.4%
9606.HK
9606.HK • China
DUALITYBIO-B
182.7 HKD
2.13B USD 1Y -42.1%
688105.SS
688105.SS • China
NANJING VAZYME BIOTECH CO LTD
26.6 CNY
2.06B USD 1Y +49.7%
1877.HK
1877.HK • China
JUNSHI BIO
17.65 HKD
2.31B USD 1Y -40.6%
600201.SS
600201.SS • China
JINYU BIO-TECHNOLOGY CO LTD
11.84 CNY
1.95B USD 1Y +21.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
44.7% p.a.
Max Drawdown (5Y)
-75.2%
Sharpe Ratio (5Y)
-0.22
Beta Factor
0.65
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 108.2 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (44.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -75.2% in the extended horizon.
ende